COVID-2019 vaccine - Chongqing Zhifei Biological Products/Institute of Microbiology of the Chinese Academy of Sciences
Alternative Names: Recombinant protein-based adjuvanted COVID-2019 vaccine - Chongqing Zhifei Biological Products/Institute of Microbiology of the Chinese Academy of SciencesLatest Information Update: 28 Mar 2024
At a glance
- Originator Chongqing Zhifei Biological Products; Institute of Microbiology of the Chinese Academy of Sciences
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in China (Parenteral)
- 01 Feb 2020 Preclinical trials in COVID-2019 infections (Prevention) in China (Parenteral)